Armand Butera

Investigators reported that the medication was safe for patients with moderate-to-severe atopic dermatitis regardless of the presence of allergic comorbidities.

Investigators collected data from 5 focus groups of community-based pediatricians to address ongoing concerns on the treatment of atopic dermatitis in this pediatric population.

Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.

Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.

Investigators report that the skin condition mediated the association between a a interleukin-4 receptor agonist variant and food allergy.

Investigators report that 21.9% of all participants with allergic contact dermatitis had 1 or more currently relevant reactions to a supplemental allergen/substance.

Investigators wrote that the phenomena can be used to evaluated clinical features of the disease, resulting in more precise therapy recommendations.

By identifying 22 key parameters in study designs, investigators hope to establish a standardized approach for analyzing moderate-to-severe atopic dermatitis trial results.

Patients and physicians alike approved of the overall design of the tool, which aided patients in identifying preventive services featured in the study.

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

Investigators noted the treatment method was well tolerated in patients who could not safely use oral cyclosporine.

Investigators believe that goal-oriented care is possible with additional lifestyle medicine training for physiatrists.

Investigators stated that prolonged maintenance dosing of the monoclonal antibody was preferred by affected patients.

Investigators reported that the efficacy of the medication is supported by a high safety profile, with fleeting and limited adverse events recorded.

Though immunogenicity responses to the vaccine were lower in dialysis patients, the lower response rate was less apparent in second doses.

Investigators called for the development of health care system structures to better support the exchanging of resources and information.

Investigators suggested the prevention of exposure during pregnancy could help control atopic dermatitis and other potential allergies in pediatric populations.

The instrument’s score was compared favorably to the Dermatology Life Quality Index and Vitiligo Impact Patient score.

Investigators noted that despite these self-reported allergic reactions, they were not an impediment for the completion of the 2-dose vaccination series.

An increase in benzodiazepine prescriptions in women patients was also reported, which suggested a substantial mental health impact of COVID-19-associated mitigation measures.

Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.

To date, dupilumab is the only medicine to show clinically meaningful phase 3 results in this patient population, with regulatory fillings planned for 2022.

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

Though high-dose ultraviolet therapy was also effective, investigators were concerned with the potential long-term adverse events.

This represents the first biologic to show positive phase 3 results in prurigo nodularis.

The REVEAL Lite 2 risk assessment tool confirmed that treatment with the agonist improved risk profile and long-term outcomes of patients with pulmonary arterial hypertension.

The risk of developing atopic dermatitis due to these combined effects is especially prevalent in infant boys with high maternal anxiety.

Investigators believe the new instrument could be generalized to other chronic inflammatory skin diseases in future studies.